Term of Research Collaboration Sample Clauses

Term of Research Collaboration. (i) The Selection Term will commence on the Effective Date and shall continue until the third (3rd) anniversary of the Effective Date (the "Selection Term"), which Selection Term may be extended for up to two (2) additional one- (1-) year periods, at Novartis's election upon the provision of written notice to Alnylam not later than ninety (90) calendar days prior to the end of the then current Selection Term. Notwithstanding the foregoing, the Selection Term may be terminated earlier pursuant to Sections 8.2 or 8.3.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Term of Research Collaboration. The Research Collaboration shall become effective on the Effective Date and continue until the expiration of the Research Collaboration Term.
Sample 1Sample 2Sample 3
Term of Research Collaboration. Except as otherwise provided in Section 12.1, the term of the Research Collaboration shall continue for a term of three (3)
Sample 1Sample 2
Term of Research Collaboration. 25 11.1.2. Term of Agreement . . . . . . . . . . . . . 25 11.2. Events of Default . . . . . . . . . . . . . . . . 25 11.2.1. Default by Either Party . . . . . . . . . . 25 11.2.2. Default by SC . . . . . . . . . . . . . . . 25 11.3. Effect of an Event of Default . . . . . . . . . . 26 11.3.1. Remedies Available to GTC . . . . . . . . . 26 11.3.2. Remedies Available to SC . . . . . . . . . . 28 11.4. * SC . . . . . . . . . . . . . . . . . . 28 11.5. Effect of Expiration or Termination of Research Collaboration . . . . . . . . . . . . . . 28 11.6. Effect of Expiration or Termination of Agreement . . . . . . . . . . . . . . . . . . . . . 29 * Confidential information omitted and filed separately with the Commission
Sample 1Sample 2
Term of Research Collaboration. Section 2.3 of the Agreement is hereby deleted in its entirety and replaced by the following:
Sample 1
Term of Research Collaboration. Unless this Agreement is sooner terminated in accordance with the provisions of this Article 11, the term of the Research Collaboration shall expire [*] months from the Effective Date; provided, however, that SC may, in its discretion, elect to extend the Research Collaboration for [*] SC shall deliver written notice to GTC at least [*] prior to the expiration of the initial term and, if applicable, any extension of the Research Collaboration definitively stating whether SC intends to exercise its option to extend the term of the Research Collaboration. In any event, GTC may, in its discretion, engage in an orderly wind-down of the Research Collaboration, including the reassignment of the scientists devoted thereto, during the last [*] thereof, provided that, GTC continues to fulfill its obligations under this Agreement.
Sample 1
Term of Research Collaboration. The term of the Research Collaboration shall be for [***] years (“Research Term”).
Sample 1
AutoNDA by SimpleDocs
Term of Research Collaboration. Unless this Agreement is sooner terminated in accordance with the provisions of this Article 11, the term of the Research Collaboration shall expire thirty (30) months from the Funding Commencement Date; provided, however, that SC may, in its discretion, elect to extend the Research Collaboration for an additional eighteen (18) months. SC shall deliver written notice to GTC at least * * prior to the expiration of the initial term of the Research Collaboration definitively stating whether SC intends to exercise its option to extend the term of the Research Collaboration. In any event, GTC may, in its discretion, engage in an orderly wind-down of the Research Collaboration, including the reassignment of the scientists devoted thereto, during the last * thereof.
Sample 1
Term of Research Collaboration. Unless this Agreement is sooner terminated in accordance with the provisions of this Article 11, the term of the Research Collaboration shall expire at the end of the *...* Contract Year; PROVIDED, HOWEVER, that the Research Collaboration may be extended upon mutual agreement of the parties, reached no later than six (6) months prior to the end of the initial term of the Research Collaboration, for up to *...* additional periods of *...* Contract Year each. In any event, GTC may, in its discretion, engage in an orderly wind-down of the Research Collaboration, including the reassignment of the scientists devoted thereto, during the last six (6) months thereof. In such an event, the financial contribution of BMI to the Research Collaboration under the terms of Article 6.4.1 shall be adjusted accordingly but shall, in no event, for such six (6) month period, fall below the sum of *...* United States dollars (*...*) in accordance with the minimum research funding amount provided for under Section 6.4.1.
Sample 1

Related to Term of Research Collaboration

  • Research Collaboration (a) GSK hereby grants to Anacor a non-exclusive, non-royalty bearing license under the GSK IP, solely as and to the extent necessary or important to conduct activities for which Anacor is responsible under the Research Plans during the Research Collaboration Term.

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

  • Research Term The Research Program will be carried out during the two (2) year period following the Effective Date, unless this Agreement is terminated in accordance with Article 13 (such period, as may be extended pursuant to this Section 3.2, being the “Research Term”). BMS shall have the option to extend the Research Term for three (3) additional one (1) year periods on a year-by-year basis after the initial two (2) year period. At least one hundred eighty (180) days prior to the scheduled expiration of the Research Term (i.e., the applicable anniversary of the Effective Date) BMS will provide Ambrx with a nonbinding, good faith indication of whether or not BMS intends to extend the Research Term. In order to exercise its option to extend the Research Term, BMS must provide Ambrx a written notice exercising BMS’ option to extend the Research Term at least ninety (90) days prior to the scheduled expiration of the Research Term (i.e., the applicable anniversary of the Effective Date). If BMS does not provide such written notice, the Research Term will end when scheduled (i.e., on the applicable anniversary of the Effective Date). For each extension of the Research Term, subject to Section 3.4, the JRC will prepare an update to the Research Plan which will include an updated Budget for the BMS-funded Ambrx FTEs to perform the work required under such Research Plan and the projected Third Party Costs.

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Collaboration Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party’s request and expense, including to be named in such action if required by Applicable Laws to pursue such action. The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party’s comments on any such efforts, including determination of litigation strategy and filing of material papers to the competent court. The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.

  • Conduct of Research Program Each Party:

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Joint Research Committee The Parties hereby establish a committee to facilitate the Research Program as follows:

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

Time is Money Join Law Insider Premium to draft better contracts faster.